We have previously shown that DNA vaccines encoding the HPV-16 E7 oncoprotein genetically fused to HSV-1 glycoprotein D (gD) enhance both the induction of E7-specific CD8+ T cell responses and therapeutic/prophylactic anti-tumor effects compared to vaccines encoding the non-fused HPV oncoproteins in mice [15], [27], [28]. Here, CD8A is linked to neoplasm.